Pritelivir: The First New Herpes Drug in 20 Years Awaits FDA Decision
Pritelivir is an oral antiviral for herpes simplex virus (HSV-1 and HSV-2) that is under FDA review, with a decision expected in the fourth quarter of 2026. If...
Read More4 articles tagged with this topic
Pritelivir is an oral antiviral for herpes simplex virus (HSV-1 and HSV-2) that is under FDA review, with a decision expected in the fourth quarter of 2026. If...
Read MoreHerpes on the buttocks, scientifically known as sacral herpes simplex virus infection, is caused primarily by the herpes simplex virus type 2 (HSV-2), and...
Read MoreHerpes simplex virus (HSV) infections, particularly genital herpes, are increasing worldwide, posing a growing public health concern. This rise results from a...
Read MoreThe rise of mpox (formerly known as monkeypox) has raised significant public health concerns, particularly because its symptoms often resemble those of herpes....
Read More